Omadacycline Noninferior to Moxifloxacin for Pneumonia

WEDNESDAY, Feb. 6, 2019 -- Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections, according to two studies published in the Feb. 7 issue of the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Extracorporeal membrane oxygenation (ECMO) for adult respiratory failure has significantly increased, with longer duration ECMO support required in severe hypoxemia. We sought to examine independent predictors of survival of adult respiratory failure patients requiring prolonged (≥14 days) ECMO. We reviewed Extracorporeal Life Support Organization Registry data on all adult (≥18 years) patients who required P- ECMO (n = 4,361) over 10 years (2009–2018). Hospital survival was 51.3%, increased from 45.4% in our prior report of 974 patients (1989–2013). Univariate analysis confirmed factors associated with d...
Source: ASAIO Journal - Category: Medical Devices Tags: Pulmonary Source Type: research
Authors: Salomaa S, Bouffler SD, Atkinson MJ, Cardis E, Hamada N Abstract Since early April 2020, there has been intense debate over proposed clinical use of ionizing radiation to treat life-threatening pneumonia in Coronavirus Disease 2019 (COVID-19) patients. At least twelve relevant papers appeared by 20 May 2020. The radiation dose proposed for clinical trials are a single dose (0.1-1 Gy) or two doses (a few mGy followed by 0.1-0.25 Gy involving a putative adaptive response, or 1-1.5 Gy in two fractions 2-3 days apart). The scientific rationale for such proposed so-called low dose radiother...
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
In conclusion, inhibition of miR-497-3p downregulates the expression of procalcitonin and ameliorates bacterial pneumonia in mice.
Source: Inflammation - Category: Allergy & Immunology Source Type: research
Clinical / Antimicrobial
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
CONCLUSIONS: There are clear associations linked to the finding of HC in sputum that may be helpful in pointing to a specific diagnosis, such as the possibility of underlying carcinoma.
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research
In this study, we show that normoxic HC increases viral replication, lung injury, and mortality in mice infected with influenza A virus (IAV). Elevated CO2 increased IAV replication and inhibited antiviral gene and protein expression in macrophages in vivo and in vitro. HC potentiated IAV-induced activation of Akt, whereas specific pharmacologic inhibition or short hairpin RNA knockdown of Akt1 in alveolar macrophages blocked HC's effects on IAV growth and the macrophage antiviral response. Our findings suggest that targeting Akt1 or the downstream pathways through which elevated CO2 signals could enhance macrophage antivi...
Source: Journal of Immunology - Category: Allergy & Immunology Authors: Tags: J Immunol Source Type: research
Community-acquired bacterial pneumonia (CABP) is a significant cause of morbidity and mortality worldwide. In the US, influenza and pneumonia are the eighth leading cause of death in people ≥65 years of age (Deaths, 2019). Approximately 1.3 million episodes of CABP occur in adults ≥65 years of age each year in the US (Yu et al., 2012). In the Etiology of Pneumonia in the Community (EPIC) study, approximately 4% of patients had the atypical pathogens M. pneumoniae, C. pneumoniae, an d L. pneumophila identified (Jain et al., 2015).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
In this study, we report the clinical and laboratory results of 57 patients with confirmed COVID-19 pneumonia and 46 patients with confirmed community-acquired bacterial pneumonia (CAP). And their concentrations of D-dimer, infection-related biomarkers, and conventional coagulation were retrospectively analyzed. The Padua prediction score is used to identify patients at high risk for venous thromboembolism (VTE). The results found that, on admission, both in COVID-19 patients and CAP patients, D-dimer levels were significantly increased, and compared with CAP patients, D-dimer levels were higher in COVID-19 patients (P  
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
KENILWORTH, N.J.--(BUSINESS WIRE) June 5, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
The FDA has approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
More News: Avelox | Bacterial Pneumonia | Linezolid | Moxifloxacin | Pharmaceuticals | Pneumonia | Skin | Study | Zyvox